Vitelliform macular dystrophy

Last updated
Vitelliform macular dystrophy
Other namesVitelliform dystrophy
Autosomal dominant - en.svg
Best disease, the early-onset form of vitelliform macular dystrophy, has an autosomal dominant pattern of inheritance.
Specialty Ophthalmology, medical genetics   OOjs UI icon edit-ltr-progressive.svg

Vitelliform macular dystrophy is an irregular autosomal dominant eye disorder which can cause progressive vision loss. [1] This disorder affects the retina, specifically cells in a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The condition is characterized by yellow (or orange), slightly elevated, round structures similar to the yolk (Latin vitellus) of an egg. [2]

Contents

Genetics

Best disease is inherited in an autosomal dominant pattern, [3] which means one copy of the altered gene in each cell is sufficient to cause the disorder. In most cases, an affected person has one parent with the condition.

The inheritance pattern of adult-onset vitelliform macular dystrophy is definitively autosomal dominant. [2] Many affected people, however, have no history of the disorder in their family and only a small number of affected families have been reported. This is because the penetrance of the condition is incomplete; therefore, it is possible for an individual to have a copy of the mutant allele and not display the VMD phenotype. The ratio of males to females is approximately 1:1. [2]

Pathophysiology

Mutations in the RDS and VMD2 genes cause vitelliform macular dystrophy. Mutations in the VMD2 gene are responsible for Best disease. Changes in either the VMD2 or RDS gene can cause the adult-onset form of vitelliform macular dystrophy; however, fewer than a quarter of cases result from mutations in these two genes. In most cases, the cause of the adult-onset form is unknown.

The VMD2 gene provides instructions for making a protein called bestrophin. [4] Although its exact function is uncertain, this protein likely acts as a channel that controls the movement of negatively charged chlorine atoms (chloride ions) into or out of cells in the retina. Mutations in the VMD2 gene probably lead to the production of an abnormally shaped channel that cannot regulate the flow of chloride. Researchers have not determined how these malfunctioning channels are related to the buildup of lipofuscin in the macula and progressive vision loss.

The RDS gene provides instructions for making a protein called peripherin. [5] This protein is essential for the normal function of light-sensing (photoreceptor) cells in the retina. Mutations in the RDS gene disrupt the structures in these cells that contain light-sensing pigments, leading to vision loss. It is unclear why RDS mutations affect only central vision in people with adult-onset vitelliform macular dystrophy.

Diagnosis

Vitelliform macular dystrophy causes a fatty yellow pigment (lipofuscin) to build up in cells underlying the macula. [6] The retinal pigment epithelium also degenerates. Over time, the abnormal accumulation of this substance can damage the cells that are critical for clear central vision. As a result, people with this disorder often lose their central vision and may experience blurry or distorted vision, and loss is rarely symmetric. Scotomata appear, first with red light and then for green; finally, relative (or in more serious cases, absolute) scotomata occur with white light. Vitelliform macular dystrophy does not affect side (peripheral) vision or the ability to see at night.

Researchers have described two forms of vitelliform macular dystrophy with similar features. The early-onset form (known as Best disease) usually appears in childhood. [7] The disease received its name from a German ophthalmologist Friedrich Best who defined a pedigree living with various stages of the disease in 1905. The onset of symptoms and the severity of vision loss vary widely. The adult-onset form begins later, usually in middle age, and tends to cause relatively mild vision loss. The two forms of vitelliform macular dystrophy each have characteristic changes in the macula that can be detected during an eye examination.

In the Best disease, the paraclinic evaluations such as fundus fluorescein angiography or indocyanine green angiography, along with baseline and final electrooculography (EOG) results, may shed the light on the progression of disease. [8] [9]

Related Research Articles

<span class="mw-page-title-main">Retinitis pigmentosa</span> Gradual retinal degeneration leading to progressive sight loss

Retinitis pigmentosa (RP) is a genetic disorder of the eyes that causes loss of vision. Symptoms include trouble seeing at night and decreasing peripheral vision. As peripheral vision worsens, people may experience "tunnel vision". Complete blindness is uncommon. Onset of symptoms is generally gradual and often begins in childhood.

<span class="mw-page-title-main">Retinoschisis</span> Eye disease involving splitting of the retina

Retinoschisis is an eye disease characterized by the abnormal splitting of the retina's neurosensory layers, usually in the outer plexiform layer. Retinoschisis can be divided into degenerative forms which are very common and almost exclusively involve the peripheral retina and hereditary forms which are rare and involve the central retina and sometimes the peripheral retina. The degenerative forms are asymptomatic and involve the peripheral retina only and do not affect the visual acuity. Some rarer forms result in a loss of vision in the corresponding visual field.

<span class="mw-page-title-main">Macular degeneration</span> Medical condition associated with vision loss

Macular degeneration, also known as age-related macular degeneration, is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur.

<span class="mw-page-title-main">Cone dystrophy</span> Medical condition

A cone dystrophy is an inherited ocular disorder characterized by the loss of cone cells, the photoreceptors responsible for both central and color vision.

Progressive retinal atrophy (PRA) is a group of genetic diseases seen in certain breeds of dogs and, more rarely, cats. Similar to retinitis pigmentosa in humans, it is characterized by the bilateral degeneration of the retina, causing progressive vision loss culminating in blindness. The condition in nearly all breeds is inherited as an autosomal recessive trait, with the exception of the Siberian Husky (inherited as an X chromosome linked trait) and the Bullmastiff (inherited as an autosomal dominant trait). There is no treatment.

Stargardt disease is the most common inherited single-gene retinal disease. In terms of the first description of the disease, it follows an autosomal recessive inheritance pattern, which has been later linked to bi-allelic ABCA4 gene variants (STGD1). However, there are Stargardt-like diseases with mimicking phenotypes that are referred to as STGD3 and STGD4, and have a autosomal dominant inheritance due to defects with ELOVL4 or PROM1 genes, respectively. It is characterized by macular degeneration that begins in childhood, adolescence or adulthood, resulting in progressive loss of vision.

<span class="mw-page-title-main">Optic pit</span> Medical condition

Optic pit, optic nerve pit, or optic disc pit (ODP) is rare a congenital excavation (or regional depression) of the optic disc (also optic nerve head), resulting from a malformation during development of the eye. The incidence of ODP is 1 in 10,000 people with no predilection for either gender. There is currently no known risk factors for their development. Optic pits are important because they are associated with posterior vitreous detachments (PVD) and even serous retinal detachments.

<span class="mw-page-title-main">ABCA4</span> Mammalian protein found in Homo sapiens

ATP-binding cassette, sub-family A (ABC1), member 4, also known as ABCA4 or ABCR, is a protein which in humans is encoded by the ABCA4 gene.

<span class="mw-page-title-main">Peripherin 2</span> Protein-coding gene in the species Homo sapiens

Peripherin-2 is a protein, that in humans is encoded by the PRPH2 gene. Peripherin-2 is found in the rod and cone cells of the retina of the eye. Defects in this protein result in one form of retinitis pigmentosa, an incurable blindness.

<span class="mw-page-title-main">Bestrophin 1</span> Protein-coding gene in the species Homo sapiens

Bestrophin-1 (Best1) is a protein that, in humans, is encoded by the BEST1 gene.

<span class="mw-page-title-main">RPE65</span> Protein-coding gene in the species Homo sapiens

Retinal pigment epithelium-specific 65 kDa protein, also known as retinoid isomerohydrolase, is an enzyme of the vertebrate visual cycle that is encoded in humans by the RPE65 gene. RPE65 is expressed in the retinal pigment epithelium and is responsible for the conversion of all-trans-retinyl esters to 11-cis-retinol during phototransduction. 11-cis-retinol is then used in visual pigment regeneration in photoreceptor cells. RPE65 belongs to the carotenoid oxygenase family of enzymes.

<span class="mw-page-title-main">Retinaldehyde-binding protein 1</span> Protein-coding gene in the species Homo sapiens

Retinaldehyde-binding protein 1 (RLBP1) also known as cellular retinaldehyde-binding protein (CRALBP) is a 36-kD water-soluble protein that in humans is encoded by the RLBP1 gene.

<span class="mw-page-title-main">ELOVL4</span> Protein-coding gene in the species Homo sapiens

Elongation of very long chain fatty acids protein 4 is a protein that in humans is encoded by the ELOVL4 gene.

<span class="mw-page-title-main">GUCA1B</span> Protein-coding gene in the species Homo sapiens

Guanylyl cyclase-activating protein 2 is an enzyme that in humans is encoded by the GUCA1B gene. Alternative names:

<span class="mw-page-title-main">Bestrophin-2</span> Protein-coding gene in the species Homo sapiens

Bestrophin-2 is a protein that in humans is encoded by the BEST2 gene.

Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness.

<span class="mw-page-title-main">Hypotrichosis with juvenile macular dystrophy</span> Medical condition

Hypotrichosis with juvenile macular dystrophy is an extremely rare congenital disease characterized by sparse hair growth (hypotrichosis) from birth and progressive macular corneal dystrophy.

Occult macular dystrophy (OMD) is a rare inherited degradation of the retina, characterized by progressive loss of function in the most sensitive part of the central retina (macula), the location of the highest concentration of light-sensitive cells (photoreceptors) but presenting no visible abnormality. "Occult" refers to the degradation in the fundus being difficult to discern. The disorder is called "dystrophy" instead of "degradation" to distinguish its genetic origin from other causes, such as age. OMD was first reported by Y. Miyake et al. in 1989.

<span class="mw-page-title-main">Progressive bifocal chorioretinal atrophy</span> Medical condition

Progressive bifocal chorioretinal atrophy, also known for its abbreviations PBCRA or CRAPB, is a rare, slowly progressive, autosomal dominant syndrome characterized by relatively large-sized atrophic hole-shaped lesions in the macular and nasal retina, myopia, low visual acuity, and nystagmus. It has been described in one family from Scotland and two families from France. The condition is caused by point mutations in a region in the long arm of chromosome 6 (6q16.2) that has been found responsible for the pathogenesis of other macular dystrophies.

References

  1. ↑ Musarella MA (May 2001). "Molecular genetics of macular degeneration". Documenta Ophthalmologica. Advances in Ophthalmology. 102 (3): 165–77. doi:10.1023/A:1017510515893. PMID   11556484.
  2. 1 2 3 Deutman A, Hoyng C, van Lith-Verhoeven J (2006). "Macular dystrophies". Retina (4 ed.). Elsevier Mosby. pp. 1177–81.
  3. ↑ Heidary F, Gharebaghi R (March 2021). "Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study". Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie. 259 (3): 787–788. doi:10.1007/s00417-020-04888-1. PMID   32785779.
  4. ↑ Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K (November 2000). "Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium". Proceedings of the National Academy of Sciences of the United States of America. 97 (23): 12758–63. doi: 10.1073/pnas.220402097 . PMC   18837 . PMID   11050159.
  5. ↑ Kohl S, Giddings I, Besch D, Apfelstedt-Sylla E, Zrenner E, Wissinger B (1998). "The role of the peripherin/RDS gene in retinal dystrophies". Acta Anatomica. 162 (2–3): 75–84. doi:10.1159/000046471. PMID   9831753.
  6. ↑ Guziewicz KE, Sinha D, Gómez NM, Zorych K, Dutrow EV, Dhingra A, et al. (May 2017). "Bestrophinopathy: An RPE-photoreceptor interface disease". Progress in Retinal and Eye Research. 58: 70–88. doi:10.1016/j.preteyeres.2017.01.005. PMC   5441932 . PMID   28111324.
  7. ↑ Heidary F, Hitam WH, Ngah NF, George TM, Hashim H, Shatriah I (March 2011). "Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy". Journal of Pediatric Ophthalmology and Strabismus. 48 Online (6): e19-22. doi:10.3928/01913913-20110308-02. PMID   21417187.
  8. ↑ Heidary F, Gharebaghi R (March 2021). "Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study". Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie. 259 (3): 787–788. doi:10.1007/s00417-020-04888-1. PMID   32785779.
  9. ↑ Orellana J, Friedman AH (1993). Best's Disease. pp. 147–150. doi:10.1007/978-1-4613-9320-7_32. ISBN   978-1-4613-9322-1.{{cite book}}: |work= ignored (help)

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.